Bavarian Nordic AS (BVNKF) reports a robust 62% revenue increase, driven by vaccine success and strategic government ...

Bavarian Nordic faced a challenging close to 2024, with Q3 revenue falling 26% compared to the same interval in 2023.

NEW YORK (AP) — The U.S. government advised American travelers age 60 and older not get a chikungunya vaccine as it ...

The earnings before interest, tax, depreciation and amortization margin rose to 31% from 3%, and Bavarian Nordic maintained guidance for a full-year EBITDA margin of 26%-30% with revenue still seen at ...

Bavarian Nordic has supplied a liquid-frozen formulation of JYNNEOS to the U.S. government for stockpiling since 2010 and in ...

Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three ...

The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

Bavarian Nordic A/S (($BVNRY)) has held its Q1 earnings call. Read on for the main highlights of the call. Bavarian Nordic’s recent earnings call ...

Good day and thank you for standing by. Welcome to the Bavarian Nordic Q1 2025 Results, Conference Call and Webcast. At this time all participants will be in a listen-only mode. After the speaker ...

Bavarian Nordic A/S ( ($BVNRY) ) has released its Q1 earnings. Here is a breakdown of the information Bavarian Nordic A/S presented to its ...

COPENHAGEN, Denmark, May 9, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three ...